Identification of a potent antiandrogen that targets the BF3 site of the androgen receptor and inhibits enzalutamide-resistant prostate cancer

Chemistry and Biology

Volumn 21, Issue 11, 2014, Pages 1476-1485

  Munuganti, Ravi S N ^a   Hassona, Mohamed D H ^a   Leblanc, Eric ^a   Frewin, Kate ^a   Singh, Kriti ^a   Ma, Dennis ^a   Ban, Fuqiang ^a   Hsing, Michael ^a   Adomat, Hans ^a   Lallous, Nada ^a   Andre, Christophe ^b   Jonadass, Jon Paul Selvam ^b   Zoubeidi, Amina ^a   Young, Robert N ^b   Tomlinson Guns, Emma ^a   Rennie, Paul S ^a   Cherkasov, Artem ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b SIMON FRASER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2,3 DIHYDRO 1H INDOL 2 YL) 1H INDOLE; ANDROGEN RECEPTOR; ANTIANDROGEN; ENZALUTAMIDE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; 3-(2,3-DIHYDRO-1H-INDOL-2-YL)-1H-INDOLE; INDOLE DERIVATIVE; PHENYLTHIOHYDANTOIN;

ARTICLE; CANCER CELL LINE; CANCER INHIBITION; DRUG BLOOD LEVEL; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; GENE EXPRESSION; HUMAN; HUMAN CELL; LNCAP CELL LINE; MAXIMUM TOLERATED DOSE; MOLECULAR DOCKING; NONHUMAN; PROSTATE CANCER; ANALOGS AND DERIVATIVES; ANIMAL; BINDING SITE; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; MALE; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS; PROTEIN TERTIARY STRUCTURE; SITE DIRECTED MUTAGENESIS; TUMOR CELL LINE; XENOGRAFT;

ANDROGEN ANTAGONISTS; ANIMALS; BINDING SITES; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; INDOLES; MALE; MICE; MICE, NUDE; MOLECULAR DOCKING SIMULATION; MUTAGENESIS, SITE-DIRECTED; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ANDROGEN; TRANSPLANTATION, HETEROLOGOUS;

EID: 84911487876     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2014.09.012     Document Type: Article

References (39)

1. V. Adamo, L. Noto, T. Franchina, G. Chiofalo, M. Picciotto, G. Toscano, and N. Caristi Emerging targeted therapies for castration-resistant prostate cancer Front. Endocrinol. (Lausanne) 3 2012 73-73
2. P. Axerio-Cilies, N.A. Lack, M.R.S. Nayana, K.H. Chan, A. Yeung, E. Leblanc, E.S.T. Guns, P.S. Rennie, and A. Cherkasov Inhibitors of androgen receptor activation function-2 (AF2) site identified through virtual screening J. Med. Chem. 54 2011 6197 6205
3. M.D. Balbas, M.J. Evans, D.J. Hosfield, J. Wongvipat, V.K. Arora, P.A. Watson, Y. Chen, G.L. Greene, Y. Shen, and C.L. Sawyers Overcoming mutation-based resistance to antiandrogens with rational drug design eLife 2 2013 e00499-e00499
4. S.P. Balk, Y.J. Ko, and G.J. Bubley Biology of prostate-specific antigen J. Clin. Oncol. 21 2003 383 391
5. Y. Benjamini, and Y. Hochberg Controlling the false discovery rate - a practical and powerful approach to multiple testing J. R. Statist. Soc B. 57 1995 289 300
6. H.M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T.N. Bhat, H. Weissig, I.N. Shindyalov, and P.E. Bourne The Protein Data Bank Nucleic Acids Res. 28 2000 235 242
7. M. Bredel, and E. Jacoby Chemogenomics: an emerging strategy for rapid target and drug discovery Nat. Rev. Genet. 5 2004 262 275
8. V. Buzón, L.R. Carbó, S.B. Estruch, R.J. Fletterick, and E. Estébanez-Perpiñá A conserved surface on the ligand binding domain of nuclear receptors for allosteric control Mol. Cell. Endocrinol. 348 2012 394 402
9. Y. Chen, N.J. Clegg, and H.I. Scher Antiandrogens and androgen-depleting therapies in prostate cancer: new agents for an established target Lancet Oncol. 10 2009 981 991
10. H. Cheng, R. Snoek, F. Ghaidi, M.E. Cox, and P.S. Rennie Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression Cancer Res. 66 2006 10613 10620
11. N.J. Clegg, J. Wongvipat, J.D. Joseph, C. Tran, S. Ouk, A. Dilhas, Y. Chen, K. Grillot, E.D. Bischoff, and L. Cai ARN-509: a novel antiandrogen for prostate cancer treatment Cancer Res. 72 2012 1494 1503
12. J.T. De Leon, A. Iwai, C. Feau, Y. Garcia, H.A. Balsiger, C.L. Storer, R.M. Suro, K.M. Garza, S. Lee, and Y.S. Kim Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells Proc. Natl. Acad. Sci. USA 108 2011 11878 11883
13. S.R. Denmeade, and J.T. Isaacs A history of prostate cancer treatment Nat. Rev. Cancer 2 2002 389 396
14. H. Ellinger-Ziegelbauer, J.M. Fostel, C. Aruga, D. Bauer, E. Boitier, S. Deng, D. Dickinson, A.C. Le Fevre, A.J. Fornace Jr., and O. Grenet Characterization and interlaboratory comparison of a gene expression signature for differentiating genotoxic mechanisms Toxicol. Sci. 110 2009 341 352
15. E. Estébanez-Perpiñá, L.A. Arnold, P. Nguyen, E.D. Rodrigues, E. Mar, R. Bateman, P. Pallai, K.M. Shokat, J.D. Baxter, and R.K. Guy A surface on the androgen receptor that allosterically regulates coactivator binding Proc. Natl. Acad. Sci. USA 104 2007 16074 16079
16. R.A. Friesner, J.L. Banks, R.B. Murphy, T.A. Halgren, J.J. Klicic, D.T. Mainz, M.P. Repasky, E.H. Knoll, M. Shelley, and J.K. Perry Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy J. Med. Chem. 47 2004 1739 1749
17. M.E. Gleave, J.T. Hsieh, H.C. Wu, A.C. von Eschenbach, and L.W.K. Chung Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors Cancer Res. 52 1992 1598 1605
18. S. Grosdidier, L.R. Carbó, V. Buzón, G. Brooke, P. Nguyen, J.D. Baxter, C. Bevan, P. Webb, E. Estébanez-Perpiñá, and J. Fernández-Recio Allosteric conversation in the androgen receptor ligand-binding domain surfaces Mol. Endocrinol. 26 2012 1078 1090
19. J.R. Gunther, A.A. Parent, and J.A. Katzenellenbogen Alternative inhibition of androgen receptor signaling: peptidomimetic pyrimidines as direct androgen receptor/coactivator disruptors ACS Chem. Biol. 4 2009 435 440
20. J.J. Irwin, T. Sterling, M.M. Mysinger, E.S. Bolstad, and R.G. Coleman ZINC: a free tool to discover chemistry for biology J. Chem. Inf. Model. 52 2012 1757 1768
21. K. Jehle, L. Cato, A. Neeb, C. Muhle-Goll, N. Jung, E.W. Smith, V. Buzon, L.R. Carbó, E. Estébanez-Perpiñá, and K. Schmitz Coregulator control of androgen receptor action by a novel nuclear receptor-binding motif J. Biol. Chem. 289 2014 8839 8851
22. H. Kuruma, H. Matsumoto, M. Shiota, J. Bishop, F. Lamoureux, C. Thomas, D. Briere, G. Los, M. Gleave, A. Fanjul, and A. Zoubeidi A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo Mol. Cancer Ther. 12 2013 567 576
23. N.A. Lack, P. Axerio-Cilies, P. Tavassoli, F.Q. Han, K.H. Chan, C. Feau, E. LeBlanc, E.T. Guns, R.K. Guy, P.S. Rennie, and A. Cherkasov Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening J. Med. Chem. 54 2011 8563 8573
24. K. Lassi, and N.A. Dawson Emerging therapies in castrate-resistant prostate cancer Curr. Opin. Oncol. 21 2009 260 265
25. V. Laudet Evolution of the nuclear receptor superfamily: early diversification from an ancestral orphan receptor J. Mol. Endocrinol. 19 1997 207 226
26. P.D. Leeson, and B. Springthorpe The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discov. 6 2007 881 890
27. H. Miyake, C. Nelson, P.S. Rennie, and M.E. Gleave Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models Cancer Res. 60 2000 2547 2554
28. H. Miyamoto, S. Yeh, G. Wilding, and C. Chang Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells Proc. Natl. Acad. Sci. USA 95 1998 7379 7384
29. A. Mullard Protein-protein interaction inhibitors get into the groove Nat. Rev. Drug Discov. 11 2012 173 175
30. R.S.N. Munuganti, E. Leblanc, P. Axerio-Cilies, C. Labriere, K. Frewin, K. Singh, M.D. Hassona, N.A. Lack, H. Li, and F. Ban Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives J. Med. Chem. 56 2013 1136 1148
31. A.A. Parent, J.R. Gunther, and J.A. Katzenellenbogen Blocking estrogen signaling after the hormone: pyrimidine-core inhibitors of estrogen receptor-coactivator binding J. Med. Chem. 51 2008 6512 6530
32. P. Ravindranathan, T.K. Lee, L. Yang, M.M. Centenera, L. Butler, W.D. Tilley, J.T. Hsieh, J.M. Ahn, and G.V. Raj Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer Nat. Comm. 4 2013 1 11
33. N. Sato, M.E. Gleave, N. Bruchovsky, P.S. Rennie, S.L. Goldenberg, P.H. Lange, and L.D. Sullivan Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model J. Steroid Biochem. Mol. Biol. 58 1996 139 146
34. H.I. Scher, K. Fizazi, F. Saad, M.E. Taplin, C.N. Sternberg, K. Miller, R. de Wit, P. Mulders, K.N. Chi, N.D. Shore AFFIRM Investigators Increased survival with enzalutamide in prostate cancer after chemotherapy N. Engl. J. Med. 367 2012 1187 1197
35. R. Snoek, H. Cheng, K. Margiotti, L.A. Wafa, C.A. Wong, E.C. Wong, L. Fazli, C.C. Nelson, M.E. Gleave, and P.S. Rennie In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors Clin. Cancer Res. 15 2009 39 47
36. P. Tavassoli, R. Snoek, M. Ray, L.G. Rao, and P.S. Rennie Rapid, non-destructive, cell-based screening assays for agents that modulate growth, death, and androgen receptor activation in prostate cancer cells Prostate 67 2007 416 426
37. C. Tran, S. Ouk, N.J. Clegg, Y. Chen, P.A. Watson, V. Arora, J. Wongvipat, P.M. Smith-Jones, D. Yoo, and A. Kwon Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 324 2009 787 790
38. K.X. Zhang, M. Moussavi, C. Kim, E. Chow, I.S. Chen, L. Fazli, W. Jia, and P.S. Rennie Lentiviruses with trastuzumab bound to their envelopes can target and kill prostate cancer cells Cancer Gene Ther. 16 2009 820 831
39. Z. Zsoldos, D. Reid, A. Simon, S.B. Sadjad, and A.P. Johnson eHiTS: a new fast, exhaustive flexible ligand docking system J. Mol. Graph. Model. 26 2007 198 212